Literature DB >> 25311921

Clinical applications involving CNS gene transfer.

Boris Kantor1, Thomas McCown2, Paola Leone3, Steven J Gray4.   

Abstract

Diseases of the central nervous system (CNS) have traditionally been the most difficult to treat by traditional pharmacological methods, due mostly to the blood-brain barrier and the difficulties associated with repeated drug administration targeting the CNS. Viral vector gene transfer represents a way to permanently provide a therapeutic protein within the nervous system after a single administration, whether this be a gene replacement strategy for an inherited disorder or a disease-modifying protein for a disease such as Parkinson's. Gene therapy approaches for CNS disorders has evolved considerably over the last two decades. Although a breakthrough treatment has remained elusive, current strategies are now considerably safer and potentially much more effective. This chapter will explore the past, current, and future status of CNS gene therapy, focusing on clinical trials utilizing adeno-associated virus and lentiviral vectors.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AAV; CNS; Canavan disease; Clinical trial; Gene therapy; Lentivirus; Parkinson's disease; Retrovirus; Vector

Mesh:

Year:  2014        PMID: 25311921      PMCID: PMC4518844          DOI: 10.1016/B978-0-12-800149-3.00002-0

Source DB:  PubMed          Journal:  Adv Genet        ISSN: 0065-2660            Impact factor:   1.944


  208 in total

Review 1.  Molecular water pumps and the aetiology of Canavan disease: a case of the sorcerer's apprentice.

Authors:  M H Baslow
Journal:  J Inherit Metab Dis       Date:  1999-04       Impact factor: 4.982

2.  Reversal of pathology in the entire brain of mucopolysaccharidosis type VII mice after lentivirus-mediated gene transfer.

Authors:  A Bosch; E Perret; N Desmaris; D Trono; J M Heard
Journal:  Hum Gene Ther       Date:  2000-05-20       Impact factor: 5.695

3.  Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach.

Authors:  K S Bankiewicz; J L Eberling; M Kohutnicka; W Jagust; P Pivirotto; J Bringas; J Cunningham; T F Budinger; J Harvey-White
Journal:  Exp Neurol       Date:  2000-07       Impact factor: 5.330

4.  Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS.

Authors:  Cédric Raoul; Toufik Abbas-Terki; Jean-Charles Bensadoun; Sandrine Guillot; Georg Haase; Jolanta Szulc; Christopher E Henderson; Patrick Aebischer
Journal:  Nat Med       Date:  2005-03-13       Impact factor: 53.440

5.  Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector.

Authors:  Dolan Sondhi; Neil R Hackett; Daniel A Peterson; Jamie Stratton; Michael Baad; Kelly M Travis; James M Wilson; Ronald G Crystal
Journal:  Mol Ther       Date:  2006-12-19       Impact factor: 11.454

6.  Nur7 is a nonsense mutation in the mouse aspartoacylase gene that causes spongy degeneration of the CNS.

Authors:  Maria Traka; Robert L Wollmann; Sonia R Cerda; Jason Dugas; Ben A Barres; Brian Popko
Journal:  J Neurosci       Date:  2008-11-05       Impact factor: 6.167

Review 7.  The treatment of movement disorders by deep brain stimulation.

Authors:  Hong Yu; Joseph S Neimat
Journal:  Neurotherapeutics       Date:  2008-01       Impact factor: 7.620

8.  Systemic delivery of MeCP2 rescues behavioral and cellular deficits in female mouse models of Rett syndrome.

Authors:  Saurabh K Garg; Daniel T Lioy; Hélène Cheval; James C McGann; John M Bissonnette; Matthew J Murtha; Kevin D Foust; Brian K Kaspar; Adrian Bird; Gail Mandel
Journal:  J Neurosci       Date:  2013-08-21       Impact factor: 6.167

9.  VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model.

Authors:  Mimoun Azzouz; G Scott Ralph; Erik Storkebaum; Lucy E Walmsley; Kyriacos A Mitrophanous; Susan M Kingsman; Peter Carmeliet; Nicholas D Mazarakis
Journal:  Nature       Date:  2004-05-27       Impact factor: 49.962

10.  Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration.

Authors:  Eugenio Montini; Daniela Cesana; Manfred Schmidt; Francesca Sanvito; Maurilio Ponzoni; Cynthia Bartholomae; Lucia Sergi Sergi; Fabrizio Benedicenti; Alessandro Ambrosi; Clelia Di Serio; Claudio Doglioni; Christof von Kalle; Luigi Naldini
Journal:  Nat Biotechnol       Date:  2006-05-28       Impact factor: 54.908

View more
  21 in total

1.  Sponge-mediated lentivirus delivery to acute and chronic spinal cord injuries.

Authors:  Aline M Thomas; Jaime L Palma; Lonnie D Shea
Journal:  J Control Release       Date:  2015-02-24       Impact factor: 9.776

2.  Hypothalamic leptin gene therapy reduces body weight without accelerating age-related bone loss.

Authors:  Russell T Turner; Michael Dube; Adam J Branscum; Carmen P Wong; Dawn A Olson; Xiaoying Zhong; Mercedes F Kweh; Iske V Larkin; Thomas J Wronski; Clifford J Rosen; Satya P Kalra; Urszula T Iwaniec
Journal:  J Endocrinol       Date:  2015-10-20       Impact factor: 4.286

3.  Downregulation of SNCA Expression by Targeted Editing of DNA Methylation: A Potential Strategy for Precision Therapy in PD.

Authors:  Boris Kantor; Lidia Tagliafierro; Jeffrey Gu; Madison E Zamora; Ekaterina Ilich; Carole Grenier; Zhiqing Y Huang; Susan Murphy; Ornit Chiba-Falek
Journal:  Mol Ther       Date:  2018-08-29       Impact factor: 11.454

4.  Timing of Gene Therapy Interventions: The Earlier, the Better.

Authors:  Steven J Gray
Journal:  Mol Ther       Date:  2016-06       Impact factor: 11.454

Review 5.  Translation of MicroRNA-Based Huntingtin-Lowering Therapies from Preclinical Studies to the Clinic.

Authors:  Jana Miniarikova; Melvin M Evers; Pavlina Konstantinova
Journal:  Mol Ther       Date:  2018-02-08       Impact factor: 11.454

6.  Lentiviral Vector Platform for the Efficient Delivery of Epigenome-editing Tools into Human Induced Pluripotent Stem Cell-derived Disease Models.

Authors:  Lidia Tagliafierro; Ekaterina Ilich; Malik Moncalvo; Jeffrey Gu; Ahila Sriskanda; Carole Grenier; Susan K Murphy; Ornit Chiba-Falek; Boris Kantor
Journal:  J Vis Exp       Date:  2019-03-29       Impact factor: 1.355

7.  Characterization of a novel adeno-associated viral vector with preferential oligodendrocyte tropism.

Authors:  S K Powell; N Khan; C L Parker; R J Samulski; G Matsushima; S J Gray; T J McCown
Journal:  Gene Ther       Date:  2016-09-15       Impact factor: 5.250

8.  Targeted gene transfer to the brain via the delivery of brain-penetrating DNA nanoparticles with focused ultrasound.

Authors:  Brian P Mead; Panagiotis Mastorakos; Jung Soo Suk; Alexander L Klibanov; Justin Hanes; Richard J Price
Journal:  J Control Release       Date:  2015-12-28       Impact factor: 9.776

9.  The lentiviral-mediated Nurr1 genetic engineering mesenchymal stem cells protect dopaminergic neurons in a rat model of Parkinson's disease.

Authors:  Xiaoxiao Wang; Wenxin Zhuang; Wenyu Fu; Xiaocui Wang; E Lv; Fengjie Li; Shuanhu Zhou; Wolf-Dieter Rausch; Xin Wang
Journal:  Am J Transl Res       Date:  2018-06-15       Impact factor: 4.060

Review 10.  Gene suppression strategies for dominantly inherited neurodegenerative diseases: lessons from Huntington's disease and spinocerebellar ataxia.

Authors:  Megan S Keiser; Holly B Kordasiewicz; Jodi L McBride
Journal:  Hum Mol Genet       Date:  2015-10-26       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.